Compare Moderna, Inc. (MRNA) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Western Union Co — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Western Union Co trades at $6.12 (market cap $1.97B). The key difference: Moderna, Inc. is far larger — about 39.9× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Western Union Co for 96 Days on average.
| MRNA | WU | |
|---|---|---|
Market Cap | $78.65B | $1.97B |
Volume | 37,373,437 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $203.46 | $10.28 |
52-Week Low | $22.36 | $5.90 |
Typical Hold Time | 59 Days | 96 Days |
Enterprise Value | $74.80B | $1.88B |
Dividend Yield | — | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Western Union (WU) trades at $6.33, up 3.6% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The stock appears fundamentally undervalued with a P/E of 5.1 and P/S of 0.5, though recent earnings misses and declining revenue trends from $4.5B in 2022 to $4.0B projected for 2026 raise concerns. The company's $200M cost-cutting plan and pending Intermex acquisition offer potential catalysts, but regulatory hurdles and margin pressures persist.
WU presents a value opportunity with deep valuation discounts, but faces significant execution risks. The 12.24% analyst buy rating reflects caution despite the stock trading below the $6.86 consensus target. Key risks include integration challenges with Intermex, competitive pressures in money transfers, and declining profitability margins. The current price near 52-week lows suggests limited downside but requires successful turnaround execution for meaningful upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
